BioCentury
ARTICLE | Cover Story

Fresh air for COPD

July 31, 2014 7:00 AM UTC

An undisclosed company has picked up an integrin-targeting antibody from the University of California, San Francisco that could address the underlying pathology in chronic obstructive pulmonary disease by improving airway remodeling via suppressing transforming growth factor-b1.1 The home run will be whether the antibody reverses existing damage.

Although there is no shortage of marketed therapies and compounds in development for chronic obstructive pulmonary disease (COPD), the compounds mostly provide symptomatic relief by opening airways and suppressing inflammation...